spot_img

Topics: ALM223

Almirall S.A. Begins First Phase Clinical Study Of ALM223

Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety,...
spot_img

Trending